48,862
edits
(→IHC) |
|||
Line 4: | Line 4: | ||
Previously, it was referred to as '''pancreatic islet cell tumour''' or '''islet cell tumour'''; thes terms are now considered to be outdated.<ref name=pmid22198808>{{Cite journal | last1 = Burns | first1 = WR. | last2 = Edil | first2 = BH. | title = Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update. | journal = Curr Treat Options Oncol | volume = | issue = | pages = | month = Dec | year = 2011 | doi = 10.1007/s11864-011-0172-2 | PMID = 22198808 }}</ref> | Previously, it was referred to as '''pancreatic islet cell tumour''' or '''islet cell tumour'''; thes terms are now considered to be outdated.<ref name=pmid22198808>{{Cite journal | last1 = Burns | first1 = WR. | last2 = Edil | first2 = BH. | title = Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update. | journal = Curr Treat Options Oncol | volume = | issue = | pages = | month = Dec | year = 2011 | doi = 10.1007/s11864-011-0172-2 | PMID = 22198808 }}</ref> | ||
Neuroendocrine tumours in general are dealt with in the ''[[neuroendocrine tumours]]'' article. | |||
==General== | ==General== | ||
*Rare. | *Rare ~ 1% of pancreatic tumours.<ref>{{Ref GLP|496}}</ref> | ||
*Presentation depends on subtype, e.g. for ''insulinoma'' the typical presentation is hypoglycemia. | *Presentation depends on subtype, e.g. for ''insulinoma'' the typical presentation is hypoglycemia. | ||
*May be part of a syndrome: | *May be part of a syndrome: | ||
Line 68: | Line 70: | ||
==See also== | ==See also== | ||
*[[Pancreas]]. | *[[Pancreas]]. | ||
*[[Neuroendocrine tumours]]. | |||
==References== | ==References== |
edits